Cost Comparison: Clotrimazole Troches vs Nystatin Suspension
Clotrimazole troches are significantly less expensive than nystatin suspension—approximately one-tenth the cost—making them the more economical choice for treating oropharyngeal candidiasis 1.
Direct Cost Evidence
A head-to-head comparative trial in renal transplant recipients definitively demonstrated that clotrimazole troches cost approximately 10% of what nystatin oral suspension costs when used in prophylactic doses 1. This represents a substantial cost savings without compromising efficacy, as both agents achieved 100% effectiveness in preventing thrush in that study.
Clinical Equivalence with Cost Advantage
The 2016 IDSA guidelines position both medications as appropriate first-line options for mild oropharyngeal candidiasis 2:
- Clotrimazole troches: 10 mg 5 times daily for 7-14 days (strong recommendation; high-quality evidence)
- Nystatin suspension: 100,000 U/mL, 4-6 mL 4 times daily for 7-14 days (strong recommendation; moderate-quality evidence)
The guidelines classify nystatin as an "alternative" rather than primary recommendation, while clotrimazole receives slightly stronger evidence grading 2.
Additional Practical Advantages of Clotrimazole
Beyond cost savings, clotrimazole troches offer:
- Better patient compliance: Significantly fewer withdrawals from therapy (1 patient vs 8 patients in the nystatin group, p=0.002) 1
- Easier self-administration: Lozenge form is simpler than liquid suspension
- Better tolerability: Fewer complaints about unpleasant taste
- Less frequent dosing: 5 times daily vs 4-6 mL 4 times daily
Important Caveat
While clotrimazole is cheaper and better tolerated, both medications are equally effective clinically. The choice should factor in cost, patient preference, and ability to comply with the lozenge dissolution requirement (clotrimazole must be slowly dissolved in the mouth, not swallowed) 3.
For patients who cannot tolerate the troche form or have difficulty with slow dissolution, nystatin suspension remains a valid alternative despite higher cost.